Here's why the EMvision (ASX:EMV) share price is up 9% this week

The EMVision share price is up by almost 10% this week, after the company announced a cash injection and a new chief scientific officer.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The EMVision Medical Devices Ltd (ASX: EMV) share price has had a bumper week so far. Shares in the medical imaging company are up by 1.94% today, on the back of a week of gains. At the time of writing, the EMVision share price is up by 9.7% since the opening bell on Monday morning.

A week of good news for EMVision

EMVision's gains this week come after the company announced on Monday that it had received a $1.28 million cash refund for the financial year ending 30 June 2020. The incentive was paid to EMVision in relation to its research and development (R&D) work.

This brings EMVision's cash reserves to $13.1 million. Cash balance is of particular interest when looking at companies involved in R&D, where there are often gaps of time in between project developments.

On Thursday morning, EMVision announced the appointment of Professor Stuart Crozier as Chief Scientific Officer, noting that he is "globally recognised for his breakthroughs in Magnetic Resonance Imaging (MRI)".

Professor Crozier will now lead R&D efforts of EMVision's novel imaging products.

So what exactly does EMVision do?

Some Fools might recall us going into detail about what EMVision gets up to back in October. The company website states that EMVision "is developing a portable brain scanner for rapid, point of care, Stroke Diagnosis and Monitoring".

If that sounds complicated, it's probably because it is! Put simply, EMVision is working toward a solution that will support people suffering from a stroke, on-site. The company is currently developing a portable brain scanner that could save significant time diagnosing a stroke, therefore potentially lessening the impact of the stroke itself. 

According to a clinical trial result the company announced back in October, "It was observed that the EMVision device was able to classify stroke type (haemorrhagic or ischaemic) with an overall accuracy of between 93.3% and 96%."

More on the EMVision share price

EMVision shares have had an impressive 12 months. Year-over-year, the share price has rocketed over 300%. During its December 2018 IPO, EMVision's price was 25 cents a share. Lately, EMVision shares are trading in the $3 range, sitting at $3.16 at the time of writing.

With a market cap of around $213 million, EMVision certainly isn't the biggest player on the field, but it seems to be garnering plenty of attention since joining the game. 

Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of EMvision Medical Devices Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A group of people push and shove through the doors of a store, trying to beat the crowd.
Broker Notes

2 ASX shares highly recommended to buy: Experts

Are these two stocks the best buys on the ASX?

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Broker Notes

These ASX 200 shares could rise 20% to 55%

Brokers have good things to say about these shares.

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Dividend Investing

I'd buy 5,883 shares of this ASX stock to aim for $1,000 of annual passive income

I’d pick this stock for its strong dividend record.

Read more »

A player pounces on the ball in the scoring zone of the field.
Best Shares

4 ASX 300 shares that ripped 100% or more in 2025

The S&P/ASX 300 Index rose 7.17% and delivered a total return, including dividends, of 10.66% in 2025.

Read more »

A little girl is about to launch down the slide with a blue sky and white clouds in the sky behind her.
Broker Notes

BHP vs. Fortescue shares: Goldman Sachs says 1 will rip and 1 will dip

Top broker Goldman Sachs upgraded its 12-month share price forecasts for BHP and Fortescue shares this week.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Brokers rate these 3 ASX shares as buys in January

These ASX shares have an exciting outlook according to experts.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why Australian Ethical, Northern Minerals, PLS, and Woodside shares are falling today

These shares are ending the week in the red. But why?

Read more »